Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02203903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Study acronym: RESOLVE
StatusRecruiting
PhasePhase 1
Started2015-04-02
View on ClinicalTrials.gov ↗
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.

Amendment record

Amended 22 times since 2014-07-29; most recent filed 2026-08-12. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-12
Amendment Study Status, Oversight v22
2025-05-29
Amendment Study Status, Oversight, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v21
2024-12-17
Amendment Study Status v20
2023-09-19
Amendment Study Status v19
2022-08-30
Amendment Study Status v18
2021-07-15
Amendment Study Status, Study Description v17
2020-07-10
Amendment Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v16
2020-04-22
Amendment Study Status, Oversight v15
2019-04-25
Amendment Study Status, Sponsor/Collaborators, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v14
2019-03-04
Amendment Study Status, Contacts/Locations v13
2018-12-17
Amendment Study Status v12
2018-11-19
Amendment Study Identification, Study Status v11
2018-10-10
Amendment Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v10
2018-05-21
Amendment Study Status, Study Description, Conditions, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v9
2017-10-30
Amendment Study Status, Eligibility v8
2016-11-21
Amendment Study Status v7
2016-10-25
Amendment Study Status, Sponsor/Collaborators, Contacts/Locations v6
2016-10-19
Amendment Study Status v5
2016-03-30
Amendment Study Status v4
2015-09-26
Amendment Study Status v3
2015-03-04
Amendment Study Status, Eligibility v2
2015-01-12
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2014-07-29
Original filing
Trial Details
NCT Number NCT02203903
Lead Sponsor Catherine Bollard
Collaborators: Children's National Research Institute, Johns Hopkins University
Conditions Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Enrollment 50 participants
Start Date 2015-04-02
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-14